Tore von Würden talks through Amgen Denmark’s focus areas of osteoporosis, cardiovascular disease, haematology, and oncology, where it hopes not…

Tashia Lentz of Biogen outlines what she sees as an increasingly tough market access environment for new treatments in Denmark and calls for greater…

MSD's Catherine Williams, a recent arrival in Copenhagen, gives her first impressions of the Danish healthcare system and pharma market, drawing on…

Julie Enevold Brooker discusses what she sees as Janssen’s responsibility to help improve the Danish healthcare system beyond just bringing…

Boehringer Ingelheim’s Nicolas Dumoulin outlines Denmark’s relevance to the German family-owned company, including the strong uptake of its…

Flemming Sonne of Denmark’s public hospital medicine procurement body Amgros outlines the scope and mission of the group, how its remit has…

The Danish Life Science Cluster is Denmark’s new national business cluster for life science technology, established in December 2020 with the goal…

Spanish native Enrique Álvarez gives an overview of Denmark’s importance to Merck as a key European early launch market, a crucial clinical trial…

Established in 2017, the Danish Medicines Council is the health technology assessment (HTA)-like body in Denmark which assesses the value for patients…

Jørgen Schøler Kristensen explains the role of the Danish Medicines Council, providing guidance about new medicines for use in the Danish hospital…

Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for…

In a wide-ranging interview, incoming director general of the Danish Medicines Agency Lars Bo Nielsen discusses the challenges that personalised…